De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial

Nitz, Ulrike; Gluz, Oleg; Graeser, Monika; Christgen, Matthias; Kuemmel, Sherko; Grischke, Eva-Maria; Braun, Michael; Augustin, Doris; Potenberg, Jochem; Krauss, Katja; Schumacher, Claudia; Forstbauer, Helmut; Reimer, Toralf; Stefek, Andrea; Fischer, Hans Holger; Pelz, Enrico; Zu Eulenburg, Christine; Kates, Ronald; Wuerstlein, Rachel; Kreipe, Hans Heinrich; Harbeck, Nadia

De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial

Author:

Nitz, Ulrike; Gluz, Oleg; Graeser, Monika; Christgen, Matthias; Kuemmel, Sherko; Grischke, Eva-Maria; Braun, Michael; Augustin, Doris; Potenberg, Jochem; Krauss, Katja; Schumacher, Claudia; Forstbauer, Helmut; Reimer, Toralf; Stefek, Andrea; Fischer, Hans Holger; Pelz, Enrico; Zu Eulenburg, Christine; Kates, Ronald; Wuerstlein, Rachel; Kreipe, Hans Heinrich; Harbeck, Nadia

Tübinger Autor(en):

Grischke, Eva-Maria

Published in:

Lancet Oncology (2022), Bd. 23, H. 5, S. 625-635

Verlagsangabe:

Elsevier Science Inc

Language:

English

Full text:

http://dx.doi.org/10.1016/S1470-2045(22)00159-0

ISSN:

1470-2045